Today's Daily Dose brings you news about FDA approval of Nabriva's new pneumonia antibiotic; Sarepta's disappointment; Vanda's receipt of Complete Response Letter for the expanded indication of HETLIOZ; and Miragen Therapeutics' anticipated milestones.
from RTT - Biotech https://ift.tt/2NiBCdl
via IFTTT
No comments:
Post a Comment